Revance to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Revance Therapeutics, Inc. (RVNC) announced its participation in upcoming investor conferences. CEO Mark J. Foley will engage in a fireside chat at the Barclays Global Healthcare Conference on March 14 at 9:00 A.M. ET in Miami, Florida. CFO Tobin Schilke will speak at the Guggenheim Healthy Altitudes Summit on March 16 at 7:45 A.M. MT in Telluride, Colorado. Live webcasts can be accessed via the Investor Relations section of Revance's website, with replays available for 90 days post-event.

Revance specializes in innovative aesthetic and therapeutic solutions, including DAXXIFY® and the RHA® Collection, enhancing patient and physician experiences.

NASHVILLE, Tenn.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (RVNC), today announced that the company will participate in the following investor conferences.

Barclays Global Healthcare Conference
Chief Executive Officer, Mark J. Foley, is scheduled to participate in a fireside chat on Tuesday, March 14, at 9:00 A.M. ET, in Miami, Florida.

Guggenheim Healthy Altitudes Summit
Chief Financial Officer, Tobin Schilke, is scheduled to participate in a fireside chat on Thursday, March 16, at 7:45 A.M. MT, in Telluride, Colorado.

Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company's website at www.revance.com. The webcast replay will be available after the conclusion of the live presentation for approximately 90 days.

About Revance

Revance is a biotechnology company setting the new standard in healthcare with innovative aesthetic and therapeutic offerings that elevate patient and physician experiences. Revance’s aesthetics portfolio of expertly created products and services, including DAXXIFY® (DaxibotulinumtoxinA-lanm) for injection, the RHA® Collection of dermal fillers, and OPUL®, the first-of-its-kind Relational Commerce platform for aesthetic practices, deliver a differentiated and exclusive offering for the company’s elite practice partners and their consumers. Revance has also partnered with Viatris Inc. to develop a biosimilar to onabotulinumtoxinA for injection, which will compete in the existing short-acting neuromodulator marketplace. Revance’s therapeutics pipeline is currently focused on muscle movement disorders including evaluating DAXXIFY® in two debilitating conditions, cervical dystonia and upper limb spasticity.

Revance is headquartered in Nashville, Tennessee, with additional office locations in Newark, Pleasanton and Irvine, California. Learn more at www.Revance.com, www.RevanceAesthetics.com, www.DAXXIFY.com, or connect with us on LinkedIn.

“Revance” and the Revance logo, DAXXIFY®, and OPUL® are registered trademarks of Revance Therapeutics, Inc.
Resilient Hyaluronic Acid® and RHA® are trademarks of TEOXANE SA.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230307005508/en/

Media

Revance Therapeutics, Inc.:

Sara Fahy, 949-887-4476

sfahy@revance.com

Investors

Revance Therapeutics, Inc.:

Jessica Serra, 510-279-6886

jessica.serra@revance.com

or

Gilmartin Group, LLC.:

Laurence Watts, 619-916-7620

laurence@gilmartinir.com

Source: Revance Therapeutics, Inc.

FAQ

When is Revance Therapeutics participating in the Barclays Global Healthcare Conference?

Revance Therapeutics will participate in the Barclays Global Healthcare Conference on March 14 at 9:00 A.M. ET.

Who is speaking for Revance Therapeutics at the Guggenheim Healthy Altitudes Summit?

CFO Tobin Schilke will represent Revance Therapeutics at the Guggenheim Healthy Altitudes Summit.

How can I access the live webcasts for the Revance conferences?

Live webcasts for the Revance conferences can be accessed from the Investor Relations section of their website.

What products does Revance Therapeutics offer?

Revance offers innovative products like DAXXIFY® and the RHA® Collection, focusing on aesthetic and therapeutic solutions.

What is the focus of Revance Therapeutics' therapeutics pipeline?

Revance's therapeutics pipeline focuses on muscle movement disorders, including evaluating DAXXIFY® for cervical dystonia and upper limb spasticity.